Home 2016-10-24T12:33:21+00:00

RadioMedix and Vect-Horus Announce Signing of a Letter of Intent to Co-Develop a Radio-Theranostic Agent for Glioblastoma

RadioMedix received $2 M SBIR Phase II Contract award from NCI NIH for the targeted alpha-emitter therapy of neuroendocrine cancers

FDA-s-Woodcock-calls-to-cut-clinical-costs-via-new-efficiencies

RadioMedix and Curium Announce FDA Fast Track Designation For 64Cu-Dotatate.

capture1

RadioMedix invited to present at the 2018 BIO-INVESTOR FORUM (San Francisco)

RadioMedix and Orano Med receive FDA Orphan Drug Designation for AlphaMedix(TM) for the treatment of neuroendocrine tumors

RadioMedix and ITM announce agreement for manufacturing of Ge-68/Ga-68 generators in U.S
clinicaltrial

RadioMedix and AREVA Med announce initiation of Phase 1 clinical trial of AlphaMedixTM, a Targeted Alpha Therapy for patients with neuroendocrine tumors

capture1

RadioMedix Selected for National Cancer Institute’s Investor Initiatives and Presentation at 2017 BIO Investor Forum

RadioMedix presented at the 2018 BIO Investor Forum in San Francisco
logos
RadioMedix and ITM announce agreement for manufacturing of Ge-68/Ga-68 generators in U.S.
ITG products
RadioMedix Selected for National Cancer Institute’s Investor Initiatives and Presentation at BIO Investor Forum
clinicaltrial
Extended partnership between Radiomedix Inc and ITM´s subsidiary ITG for exclusive distribution of n.c.a Lutetium-177 in North America
RadioMedix Inc. and AREVA Med Announce Completion of the Exploratory Clinical Trial of 203Pb-AR-RMX in patients expressing somatostatin receptor positive neuroendocrine tumors
Slide thumbnail
RadioMedix and AREVA Med - SBIR NCI Contract awarded to develop targeted alpha-emitter therapy of neuroendocrine tumors with lead-212.
RadioMedix, Inc., received an exclusive distributions rights for SEDECAL Preclinical PET-CT and PET-MR systems in North America.

NCI SBIR Phase I Contract Award for targeted alpha-emitter therapy of metastatic melanoma

NIH NCI SBIR Contract Award for targeted alpha-TAT of metastatic melanoma. The third collaborative grant for RadioMedix and Viewpoint.

RadioMedix wins NIH NCI SBIR Phase I Grant

Innovating Theranostics

RadioMedix, Inc. is a biotechnology company, based in Houston, Texas, focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring and therapy of cancer. The company is commercializing generator-produced radiopharmaceuticals based on Gallium-68 chemistry. RadioMedix is in late-stage development of a new radiolabeled analog targeting metabolic pathway, GlucoMedix, which is based on its patented DO2A-chelation technology.

RadioMedix is introducing the SmartMedix™ automated laboratory system for synthesis of PET tracers for the research and clinical markets. RadioMedix has also established two service facilities for academic and industrial partners: cGMP Manufacturing Suite for clinical probe development and Molecular Imaging Facility for evaluation of agents in animal models.

Recent News


RadioMedix and Vect-Horus Announce Signing of a Letter of Intent to Co-Develop a Radio-Theranostic Agent for Glioblastoma

March 12th, 2019|Comments Off on RadioMedix and Vect-Horus Announce Signing of a Letter of Intent to Co-Develop a Radio-Theranostic Agent for Glioblastoma

RadioMedix received $2 M SBIR Phase II Contract award from NCI NIH for the targeted alpha-emitter therapy of neuroendocrine cancers

January 21st, 2019|Comments Off on RadioMedix received $2 M SBIR Phase II Contract award from NCI NIH for the targeted alpha-emitter therapy of neuroendocrine cancers

RadioMedix and Curium Announce FDA Fast Track Designation For 64Cu-Dotatate.

January 9th, 2019|Comments Off on RadioMedix and Curium Announce FDA Fast Track Designation For 64Cu-Dotatate.

RadioMedix presented at the 2018 BIO Investor Forum in San Francisco

December 14th, 2018|Comments Off on RadioMedix presented at the 2018 BIO Investor Forum in San Francisco

RadioMedix and Orano Med receive FDA Orphan Drug Designation for AlphaMedix(TM) for the treatment of neuroendocrine tumors

November 13th, 2018|Comments Off on RadioMedix and Orano Med receive FDA Orphan Drug Designation for AlphaMedix(TM) for the treatment of neuroendocrine tumors

RadioMedix and ITM announce agreement for manufacturing of Ge-68/Ga-68 generators in U.S.

July 25th, 2018|Comments Off on RadioMedix and ITM announce agreement for manufacturing of Ge-68/Ga-68 generators in U.S.